Exencial Wealth Advisors LLC Decreases Position in IQVIA Holdings Inc. (NYSE:IQV)

Exencial Wealth Advisors LLC lowered its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.9% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 42,856 shares of the medical research company's stock after selling 2,186 shares during the period. Exencial Wealth Advisors LLC's holdings in IQVIA were worth $8,422,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in IQV. Capital Performance Advisors LLP purchased a new position in IQVIA in the 3rd quarter worth approximately $27,000. Synergy Asset Management LLC purchased a new position in shares of IQVIA in the fourth quarter worth $33,000. Avior Wealth Management LLC lifted its holdings in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after purchasing an additional 87 shares in the last quarter. Assetmark Inc. boosted its position in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock valued at $54,000 after buying an additional 196 shares during the last quarter. Finally, Ashton Thomas Securities LLC bought a new stake in IQVIA in the 3rd quarter worth about $57,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analysts Set New Price Targets

Several research firms have issued reports on IQV. Robert W. Baird lowered their target price on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 21st. Royal Bank of Canada restated an "outperform" rating and set a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. Truist Financial reaffirmed a "buy" rating and issued a $263.00 target price (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. JPMorgan Chase & Co. lowered their price target on IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a report on Tuesday, February 18th. Finally, Bank of America reduced their price objective on IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a research report on Friday, December 13th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and an average price target of $249.05.

IQVIA Price Performance

Shares of NYSE IQV traded up $0.76 during mid-day trading on Thursday, reaching $186.61. The company's stock had a trading volume of 245,141 shares, compared to its average volume of 1,204,803. The stock has a fifty day moving average of $198.24 and a two-hundred day moving average of $213.66. The firm has a market capitalization of $32.90 billion, a PE ratio of 24.91, a P/E/G ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 52 week low of $179.28 and a 52 week high of $261.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.